{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.8","upperLimit":"95.5","value":"82.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"title":"Received SCT"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.3","upperLimit":"73.1","value":"64.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"118"}],"units":"Participants"}],"title":"Did not receive SCT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"}],"units":"Participants"}],"description":"Adjusted percentage of patients who were event free at 3 years. For patients who received matched donor SCT, EFS was adjusted to start from the actual SCT date. For patients who did not undergo SCT, EFS was adjusted to start from median time to SCT based on patients who received matched related SCT (where patients who had events prior to SCT date were excluded from the calculation of median time to SCT).","dispersionType":"95% Confidence Interval","groups":[{"description":"Standard VCR dosing (1.5 mg/m\\^2, max 2 mg)","id":"OG000","title":"Regimen A: Standard Vincristine Dosing"}],"paramType":"NUMBER","populationDescription":"The analysis is limited to eligible patients on Standard VCR dosing who received matched related SCT, excluding patients who had events prior to receiving SCT. And those patients on Regimen A who did not undergo SCT, excluding patients who went off therapy prior to the adjusted starting time.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Adjusted Event Free Survival","type":"SECONDARY","unitOfMeasure":"adjusted percentage of participants"}